As this happened, UBS reiterated its Cumberland Pharmaceuticals Inc [CPIX] rating to a Neutral in a research note published on November 12, 2012; the price target was $5. A number of analysts have revised their coverage, including UBS’s analysts, who remained covering the stock and in early February has reiterated a ‘”a Neutral”‘ rating for it. UBS also remained covering CPIX and has decreased its forecast on December 16, 2010 with a “Neutral” recommendation from previously “Buy” rating. UBS maintained its rating on August 17, 2010. It rated CPIX as “a Buy”.
Price Performance Review of CPIX
On Tuesday, Cumberland Pharmaceuticals Inc [NASDAQ:CPIX] saw its stock jump 14.59% to $2.67. Over the last five days, the stock has gained 16.59%. Cumberland Pharmaceuticals Inc shares have risen nearly 12.66% since the year began. Nevertheless, the stocks have risen 25.94% over the past one year. While a 52-week high of $3.05 was reached on 01/14/25, a 52-week low of $1.04 was recorded on 01/03/25. SMA at 50 days reached $1.71, while 200 days put it at $1.51.
Levels Of Support And Resistance For CPIX Stock
The 24-hour chart illustrates a support level at 1.99, which if violated will result in even more drops to 1.32. On the upside, there is a resistance level at 3.64. A further resistance level may holdings at 4.61. The Relative Strength Index (RSI) on the 14-day chart is 67.72, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 71.59%. Stochastics %K at 34.87% indicates the stock is a holding.
How much short interest is there in Cumberland Pharmaceuticals Inc?
A steep rise in short interest was recorded in Cumberland Pharmaceuticals Inc stocks on 2024-12-31, growing by 0.31 million shares to a total of 0.48 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 0.16 million shares. There was a rise of 65.66%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 17, 2010 when Morgan Joseph resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $10.
